Finding novel drugs based on the understanding of a target tissue is called Drug design. Drug design, in its most basic form, is creating molecules that are complementary in charge and shape to the target molecule by which drugs interact and bind. In the big data age, drug design commonly but not always depends on computer modelling methods and bioinformatics strategies. Biopharmaceuticals, particularly therapeutic antibodies, are a class of drugs that are becoming more and more significant in addition to small molecules, and computational methods have made significant strides in enhancing the affinity, selectivity, and stability of these protein-based therapeutics [3]. Preclinical research using animal and cell-based models, human clinical trials, and then the last phase of securing regulatory approval to sell the medicine make up drug development and discovery. The process of modern drug development includes the identification of screening hits, medicinal chemistry, and optimization of those hits to enhance their affinity, efficacy/potency, metabolic stability (to lengthen the half-life), and oral bioavailability. Prior to clinical trials, medication development will start after a molecule that satisfies all of these criteria has been found.
Vladlen Slepak
University of Miami, United States
Axel H Schonthal
University of Southern California, United States
Bernd Blobel
University of Regensburg, Germany
Consolato M Sergi
University of Alberta, Canada
Luis Jesus Villarreal Gomez
Universidad Autónoma de Baja California, Mexico
Anil Pareek
Anand Pharmacy College, India
Saad Tayyab
UCSI University, Malaysia
Lan Wang
Paretor LLC, United States
Ravi P Sahu
Wright State University, United States
Tanuja Tummala
Harrisburg University of Science and Technology, United StatesSubmit your abstract Today
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami, United States
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, University of Alberta, Canada
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : R&D consultancy at the medicines discovery catapult: De-risking drug discovery for innovators
Adriana Gambardella, Medicine Discovery Catapult, United Kingdom
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : Precision diagnostics: Effectiveness of innovative imaging technologies for early detection of lung cancers
Huiqin Yang, ICON Clinical Research Ltd, United Kingdom
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Design and characterization of gum arabic buccal films for protein drug delivery
Krisztian Pamlenyi, University of Szeged, Hungary
Title : Advancing EGFR-targeting macrocyclic peptide-drug conjugates to target KRAS-mutant solid tumors: Design, synthesis, and preclinical evaluations
Akash Panja, Ariel University, Israel